Free Trial

Compass Therapeutics (CMPX) Competitors

Compass Therapeutics logo
$2.64 -0.14 (-5.04%)
Closing price 04:00 PM Eastern
Extended Trading
$2.71 +0.07 (+2.61%)
As of 05:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CMPX vs. ETNB, ANIP, MESO, EWTX, JANX, TVTX, CVAC, CALT, GPCR, and AUPH

Should you be buying Compass Therapeutics stock or one of its competitors? The main competitors of Compass Therapeutics include 89BIO (ETNB), ANI Pharmaceuticals (ANIP), Mesoblast (MESO), Edgewise Therapeutics (EWTX), Janux Therapeutics (JANX), Travere Therapeutics (TVTX), CureVac (CVAC), Calliditas Therapeutics AB (publ) (CALT), Structure Therapeutics (GPCR), and Aurinia Pharmaceuticals (AUPH). These companies are all part of the "pharmaceutical products" industry.

Compass Therapeutics vs. Its Competitors

89BIO (NASDAQ:ETNB) and Compass Therapeutics (NASDAQ:CMPX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, dividends, valuation, analyst recommendations and media sentiment.

68.4% of Compass Therapeutics shares are held by institutional investors. 2.8% of 89BIO shares are held by insiders. Comparatively, 29.8% of Compass Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Compass Therapeutics has higher revenue and earnings than 89BIO. Compass Therapeutics is trading at a lower price-to-earnings ratio than 89BIO, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
89BION/AN/A-$367.08M-$3.38-3.02
Compass Therapeutics$850K429.48-$49.38M-$0.41-6.44

Compass Therapeutics' return on equity of -42.47% beat 89BIO's return on equity.

Company Net Margins Return on Equity Return on Assets
89BION/A -81.44% -70.17%
Compass Therapeutics N/A -42.47%-38.31%

In the previous week, Compass Therapeutics had 3 more articles in the media than 89BIO. MarketBeat recorded 3 mentions for Compass Therapeutics and 0 mentions for 89BIO. Compass Therapeutics' average media sentiment score of 0.86 beat 89BIO's score of 0.00 indicating that Compass Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
89BIO Neutral
Compass Therapeutics Positive

89BIO currently has a consensus price target of $26.43, suggesting a potential upside of 158.60%. Compass Therapeutics has a consensus price target of $12.67, suggesting a potential upside of 379.80%. Given Compass Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Compass Therapeutics is more favorable than 89BIO.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
89BIO
0 Sell rating(s)
2 Hold rating(s)
4 Buy rating(s)
2 Strong Buy rating(s)
3.00
Compass Therapeutics
0 Sell rating(s)
0 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
3.10

89BIO has a beta of 1.28, indicating that its share price is 28% more volatile than the S&P 500. Comparatively, Compass Therapeutics has a beta of 1.48, indicating that its share price is 48% more volatile than the S&P 500.

Summary

Compass Therapeutics beats 89BIO on 13 of the 15 factors compared between the two stocks.

Get Compass Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CMPX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CMPX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CMPX vs. The Competition

MetricCompass TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$365.06M$2.86B$5.45B$8.93B
Dividend YieldN/A2.44%5.22%4.01%
P/E Ratio-6.4420.4427.2420.06
Price / Sales429.48283.79426.37117.54
Price / CashN/A41.7026.2128.59
Price / Book2.907.397.925.56
Net Income-$49.38M-$55.04M$3.17B$248.56M
7 Day Performance1.54%3.43%4.40%7.56%
1 Month Performance5.60%0.16%2.64%8.54%
1 Year Performance230.00%4.49%35.04%21.81%

Compass Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CMPX
Compass Therapeutics
3.2196 of 5 stars
$2.64
-5.0%
$12.67
+379.8%
+246.9%$365.06M$850K-6.4420
ETNB
89BIO
1.5578 of 5 stars
$9.82
-0.4%
$26.43
+169.1%
+34.8%$1.43BN/A-2.9140
ANIP
ANI Pharmaceuticals
3.64 of 5 stars
$65.25
-0.4%
$80.13
+22.8%
+6.3%$1.41B$614.38M-51.38600Positive News
MESO
Mesoblast
2.1164 of 5 stars
$10.89
-0.3%
$18.00
+65.3%
+39.4%$1.39B$5.67M0.0080
EWTX
Edgewise Therapeutics
2.6397 of 5 stars
$13.11
-0.5%
$40.00
+205.1%
-33.3%$1.38BN/A-8.4660
JANX
Janux Therapeutics
2.0295 of 5 stars
$23.10
-0.2%
$95.25
+312.3%
-38.5%$1.37B$10.59M-16.9930
TVTX
Travere Therapeutics
3.1794 of 5 stars
$14.80
+0.2%
$32.14
+117.2%
+90.1%$1.31B$233.18M-5.27460
CVAC
CureVac
4.5174 of 5 stars
$5.43
+0.9%
$6.83
+25.8%
+64.0%$1.22B$579.18M5.90880
CALT
Calliditas Therapeutics AB (publ)
N/A$40.00
flat
N/AN/A$1.19B$1.60B-21.62180
GPCR
Structure Therapeutics
2.6575 of 5 stars
$20.74
-1.6%
$76.17
+267.2%
-45.4%$1.19BN/A-23.84136
AUPH
Aurinia Pharmaceuticals
2.9053 of 5 stars
$8.47
-2.0%
$11.50
+35.8%
+34.9%$1.14B$235.13M30.25300

Related Companies and Tools


This page (NASDAQ:CMPX) was last updated on 7/7/2025 by MarketBeat.com Staff
From Our Partners